Literature DB >> 8035021

Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine.

E E Walsh1.   

Abstract

The efficacy of topical immunization with the respiratory syncytial virus (RSV) fusion (F) protein was tested in mice using cholera toxin B chain (CTB) as an adjuvant. The dose of CTB required for the adjuvant effect (as measured by local and systemic antibody stimulation) and protection from viral challenge was > or = 5 micrograms. With this dose, mice immunized intranasally with CTB plus F protein were highly protected from viral replication in the upper and lower respiratory tract. This protection was associated with the induction of mucosal IgA and serum IgG and neutralizing antibody. Addition of parenteral immunization with F protein to the topical vaccination provided protection from viral challenge nearly equivalent to immunization with live RSV intranasally. Topical and parenteral immunization with F protein was not associated with induction of splenic cytotoxic T cells, in contrast to live virus given intranasally.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035021     DOI: 10.1093/infdis/170.2.345

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Nasal vaccination induces protective immunity without immunopathology.

Authors:  T Hussell; I R Humphreys
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

2.  Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.

Authors:  Fu-Shi Quan; Yonghwan Kim; Sujin Lee; Hong Yi; Sang-Moo Kang; Jadranka Bozja; Martin L Moore; Richard W Compans
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

3.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Lioubov M Pletneva; Kari Ann Shirey; Stefanie N Vogel
Journal:  Vaccine       Date:  2013-11-16       Impact factor: 3.641

5.  A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.

Authors:  D Chargelegue; O E Obeid; S C Hsu; M D Shaw; A N Denbury; G Taylor; M W Steward
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.

Authors:  Heinz Arnold; Dirk Bumann; Melanie Felies; Britta Gewecke; Meike Sörensen; J Engelbert Gessner; Joachim Freihorst; Bernd Ulrich von Specht; Ulrich Baumann
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

Review 7.  Respiratory syncytial virus infection in adults.

Authors:  A R Falsey; E E Walsh
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

Review 8.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

Review 9.  Understanding the mechanisms of viral induced asthma: new therapeutic directions.

Authors:  Nicole G Hansbro; Jay C Horvat; Peter A Wark; Philip M Hansbro
Journal:  Pharmacol Ther       Date:  2008-01-29       Impact factor: 12.310

10.  The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice.

Authors:  R L Ferrero; J M Thiberge; I Kansau; N Wuscher; M Huerre; A Labigne
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.